Latest Headlines

Latest Headlines

Manufacturing continues to undercut Ranbaxy

Ranbaxy Laboratories says it is back in the generic Lipitor game, having repaired its most recent manufacturing problems at a plant in India. Now it must also restart the process of repairing its reputation as a top generics manufacturer after yet another manufacturing foul-up and surprising analysts with an unexpected quarterly loss.

Ranbaxy back in gear for generic Lipitor production

Ranbaxy Laboratories is back in the generic Lipitor saddle again. Three months after stopping production of the cholesterol fighter and recalling almost a half-million bottles, the Indian drugmaker says it is restarting production for the U.S. market.

Ranbaxy minces no words in legal slugfest over generic Lipitor recall

A recall of generic Lipitor had already devastated Ranbaxy Laboratories' market share and entangled it in litigation. Now it has sparked a war of words between the Indian drugmaker and lawyers for consumers who say they were injured by products believed to have been tainted by glass particles.

Actavis future very bright despite tough quarter

Actavis, the former Watson Pharmaceuticals, said its fourth-quarter earnings paled by comparison to a year ago when it first released an official generic of Lipitor.

Ranbaxy production glitch devastates its generic Lipitor biz

India's Ranbaxy Laboratories' manufacturing problems have devastated its share of the U.S. generic Lipitor market. On top of that, an expanded lawsuit in New Jersey seeks to have the drugmaker recall all of the drug that it has in the U.S.

Fighting the $9B ghost of Lipitor past, Pfizer points to new drugs

Pfizer ($PFE) racked up a 46% increase in full-year profits. But its sales fell 10%. How so? Pfizer's sale of the nutrition business, which went to Nestle for $11.85 billion, helped boost reported net income to $14.57 billion.

J&J, Pfizer, BMS, Novo score, while Mylan and Par strike out

While FiercePharma 's newsletter went on hiatus over the winter holidays--and industry news slowed to a pace suitable to hibernation-friendly weather--we didn't spend all our time skiing and drinking cocoa. Some certifiably big news broke last week. Here are several holiday highlights.

UPDATED: Court thwarts Mylan attack on Ranbaxy Diovan exclusivity

It is another swing and a miss for Mylan. Twice now it has struck out in efforts to snatch away from Ranbaxy Laboratories the Indian drugmaker's 180-day exclusivity on a drug.

Pfizer targets 600 primary-care sales jobs

It's the end of the year, and the end of the road for hundreds of Pfizer drug reps. The company is slashing its primary-care sales force by almost 20%, Bloomberg reports, taking its 3,000-strong army of reps down to around 2,400.

U.S. branded sales to end 2012 with 3.5% decline

By the time the ball drops in Times Square this year, branded drug sales will have dropped 3.5%. So says a new report on U.S. spending, which pegs this year's decline at that rate--and forecasts an annual decline of 2.6%, on average, over the next several years.